IMMUNOCELLULAR THERAPEUTICS, LTD. (NYSEMKT:IMUC) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

IMMUNOCELLULAR THERAPEUTICS, LTD. (NYSEMKT:IMUC) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Story continues below

Item5.02. Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

(c)

On April14, 2017, the board of directors of ImmunoCellular
Therapeutics, Ltd. (the Company) appointed David Fractor as Chief
Financial Officer of the Company, effective immediately.
Mr.Fractor previously served as the Companys Treasurer and Chief
Financial Officer on a part-time basis from April 2011 to March
2013 and as the Companys Vice President of Finance and Principal
Accounting Officer on a part-time basis from March 2013 to April
2017. Since 2003, Mr.Fractor has been a consultant providing
financial consulting and strategic planning services, including
Sarbanes-Oxley compliance consulting services, to a variety of
companies in a variety of industries. Mr.Fractor received his
B.S. in Accounting from the University of Southern California in
1982 and is a certified public accountant and a member of AICPA
and the California Society of CPAs.

There is no arrangement or understanding between Mr.Fractor and
any other persons to which Mr.Fractor was selected as Chief
Financial Officer of the Company. There are no family
relationships between Mr.Fractor and any director or executive
officer of the Company and, other than as described above, no
transactions involving Mr.Fractor that would require disclosure
under Item404(a) of Regulation S-K.


About IMMUNOCELLULAR THERAPEUTICS, LTD. (NYSEMKT:IMUC)

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company’s cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing. In addition, the Company also has a portfolio of other potential therapeutic immunotherapies using a range of approaches to treat cancer. Its other product candidates are ICT-140 and ICT-121. ICT-107 is a dendritic cell (DC) vaccine for the treatment of newly diagnosed glioblastoma multiforme (GBM), a type of brain cancer. ICT-140 is a DC vaccine that targets over seven tumor-associated antigens expressed on ovarian cancer cells. It is developing ICT-121, a dendritic cell (DC)-based vaccine targeting CD133+ CSCs for the treatment of recurrent GBM and other solid tumor cancers, including ovarian, pancreatic and breast cancers.

IMMUNOCELLULAR THERAPEUTICS, LTD. (NYSEMKT:IMUC) Recent Trading Information

IMMUNOCELLULAR THERAPEUTICS, LTD. (NYSEMKT:IMUC) closed its last trading session up +0.02 at 2.55 with 42,495 shares trading hands.

An ad to help with our costs